Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
Although there are many patients with brain tumors worldwide, there are numerous difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year survival rate of 5.1%, is the most malignant. In addition to surgical operations, chemotherapy and radiotherapy are generally perf...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/10/5111 |
| _version_ | 1797534455389224960 |
|---|---|
| author | Jaewan Jeon Sungmin Lee Hyunwoo Kim Hyunkoo Kang HyeSook Youn Sunmi Jo BuHyun Youn Hae Yu Kim |
| author_facet | Jaewan Jeon Sungmin Lee Hyunwoo Kim Hyunkoo Kang HyeSook Youn Sunmi Jo BuHyun Youn Hae Yu Kim |
| author_sort | Jaewan Jeon |
| collection | DOAJ |
| description | Although there are many patients with brain tumors worldwide, there are numerous difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year survival rate of 5.1%, is the most malignant. In addition to surgical operations, chemotherapy and radiotherapy are generally performed, but the patients have very limited options. Temozolomide is the most commonly prescribed drug for patients with glioblastoma. However, it is difficult to completely remove the tumor with this drug alone. Therefore, it is necessary to discuss the potential of anticancer drugs, other than temozolomide, against glioblastomas. Since the discovery of cisplatin, platinum-based drugs have become one of the leading chemotherapeutic drugs. Although many studies have reported the efficacy of platinum-based anticancer drugs against various carcinomas, studies on their effectiveness against brain tumors are insufficient. In this review, we elucidated the anticancer effects and advantages of platinum-based drugs used in brain tumors. In addition, the cases and limitations of the clinical application of platinum-based drugs are summarized. As a solution to overcome these obstacles, we emphasized the potential of a novel approach to increase the effectiveness of platinum-based drugs. |
| first_indexed | 2024-03-10T11:29:47Z |
| format | Article |
| id | doaj.art-7d4511f0ef624cc29dad34c4089d2b11 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T11:29:47Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7d4511f0ef624cc29dad34c4089d2b112023-11-21T19:20:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-012210511110.3390/ijms22105111Revisiting Platinum-Based Anticancer Drugs to Overcome GliomasJaewan Jeon0Sungmin Lee1Hyunwoo Kim2Hyunkoo Kang3HyeSook Youn4Sunmi Jo5BuHyun Youn6Hae Yu Kim7Department of Radiation Oncology, Haeundae Paik Hospital, Inje University School of Medicine, Busan 48108, KoreaDepartment of Integrated Biological Science, Pusan National University, Busan 46241, KoreaDepartment of Integrated Biological Science, Pusan National University, Busan 46241, KoreaDepartment of Integrated Biological Science, Pusan National University, Busan 46241, KoreaDepartment of Integrative Bioscience and Biotechnology, Sejong University, Seoul 05006, KoreaDepartment of Radiation Oncology, Haeundae Paik Hospital, Inje University School of Medicine, Busan 48108, KoreaDepartment of Integrated Biological Science, Pusan National University, Busan 46241, KoreaDepartment of Neurosurgery, Haeundae Paik Hospital, Inje University School of Medicine, Busan 48108, KoreaAlthough there are many patients with brain tumors worldwide, there are numerous difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year survival rate of 5.1%, is the most malignant. In addition to surgical operations, chemotherapy and radiotherapy are generally performed, but the patients have very limited options. Temozolomide is the most commonly prescribed drug for patients with glioblastoma. However, it is difficult to completely remove the tumor with this drug alone. Therefore, it is necessary to discuss the potential of anticancer drugs, other than temozolomide, against glioblastomas. Since the discovery of cisplatin, platinum-based drugs have become one of the leading chemotherapeutic drugs. Although many studies have reported the efficacy of platinum-based anticancer drugs against various carcinomas, studies on their effectiveness against brain tumors are insufficient. In this review, we elucidated the anticancer effects and advantages of platinum-based drugs used in brain tumors. In addition, the cases and limitations of the clinical application of platinum-based drugs are summarized. As a solution to overcome these obstacles, we emphasized the potential of a novel approach to increase the effectiveness of platinum-based drugs.https://www.mdpi.com/1422-0067/22/10/5111platinum-based anticancer drugsbrain tumorsdrug resistancetherapeutic efficacy |
| spellingShingle | Jaewan Jeon Sungmin Lee Hyunwoo Kim Hyunkoo Kang HyeSook Youn Sunmi Jo BuHyun Youn Hae Yu Kim Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas International Journal of Molecular Sciences platinum-based anticancer drugs brain tumors drug resistance therapeutic efficacy |
| title | Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas |
| title_full | Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas |
| title_fullStr | Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas |
| title_full_unstemmed | Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas |
| title_short | Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas |
| title_sort | revisiting platinum based anticancer drugs to overcome gliomas |
| topic | platinum-based anticancer drugs brain tumors drug resistance therapeutic efficacy |
| url | https://www.mdpi.com/1422-0067/22/10/5111 |
| work_keys_str_mv | AT jaewanjeon revisitingplatinumbasedanticancerdrugstoovercomegliomas AT sungminlee revisitingplatinumbasedanticancerdrugstoovercomegliomas AT hyunwookim revisitingplatinumbasedanticancerdrugstoovercomegliomas AT hyunkookang revisitingplatinumbasedanticancerdrugstoovercomegliomas AT hyesookyoun revisitingplatinumbasedanticancerdrugstoovercomegliomas AT sunmijo revisitingplatinumbasedanticancerdrugstoovercomegliomas AT buhyunyoun revisitingplatinumbasedanticancerdrugstoovercomegliomas AT haeyukim revisitingplatinumbasedanticancerdrugstoovercomegliomas |